Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 5—May 2010

Research

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

Gerwin D. Rodenburg1Comments to Author , Sabine C. de Greeff1, Angelique G.C.S. Jansen, Hester E. de Melker, Leo M. Schouls, Eelko Hak, Lodewijk Spanjaard, Elisabeth A.M. Sanders2, and Arie van der Ende2
Author affiliations: Wilhelmina Children’s Hospital/University Medical Center, Utrecht, the Netherlands (G.D. Rodenburg, A.G.C.S Jansen, E. Hak, E.A.M. Sanders); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (S.C. de Greeff, H.E. de Melker, L.M. Schouls); University Medical Center, Groningen, the Netherlands (E. Hak); Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, the Netherlands (L. Spanjaard, A. van der Ende); 1, 2These pairs of authors contributed equally to this study.

Main Article

Figure 5

Age group–specific theoretical coverage of pneumococcal conjugate vaccines during the preimplementation and postimplementation periods of 7-valent pneumococcal conjugate vaccine (PCV-7), the Netherlands. IPD, invasive pneumococcal disease; PCV-10/PCV13, additional coverage by PCV-10 and PCV-13; PCV-13, additional coverage by PCV-13 alone; pre, preimplementation period (June 2004–June 2006); post, postimplementation period (June 2006–June 2008).

Figure 5. Age group–specific theoretical coverage of pneumococcal conjugate vaccines during the preimplementation and postimplementation periods of 7-valent pneumococcal conjugate vaccine (PCV-7), the Netherlands. IPD, invasive pneumococcal disease; PCV-10/PCV13, additional coverage by PCV-10 and PCV-13; PCV-13, additional coverage by PCV-13 alone; pre, preimplementation period (June 2004–June 2006); post, postimplementation period (June 2006–June 2008).

Main Article

1, 2These pairs of authors contributed equally to this study.

TOP